In a report released today, Peter Lawson from Barclays assigned a Buy rating to Arcus Biosciences (RCUS – Research Report), with a price target of $29.00. The company’s shares closed yesterday at ...
A popular parking spot for cash during the pandemic could offer investors a lower rate come December. That's Joseph Abate, a rates strategist at Barclays, responding to minutes of the Federal ...
Some results have been hidden because they may be inaccessible to you